Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8441094 | European Journal of Cancer | 2016 | 10 Pages |
Abstract
While the model needs to be fed with more and especially recent data before being fully ready for use in clinical practice, it could already distinguish between patients with high and low potential benefits from proton therapy. Benefits are highest for patients with both good prognosis and high expected damage to adjacent organs. The model allows for selecting such patients a priori based on patient relevant outcomes.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
E.H. Quik, T.L. Feenstra, D. Postmus, B.J. Slotman, C.R. Leemans, P.F.M. Krabbe, J.A. Langendijk,